NOTTINGHAM, England - May 15th, 2008 -- Novozymes has announced that it has granted non-exclusive licenses for its proprietary albumin fusion technology, albufuse(tm), and yeast-based expression platform to Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs. Under the terms of the agreement, Dyax has been granted a non-exclusive research and development license for use of Novozymes' technology to develop albumin fusions of Kunitz domain proteins and antibody fragments for therapeutic and diagnostic applications.
